Kuhnil Signs Exclusive Marketing Rights for Senju’s Bronuck

Published: 2004-12-28 06:54:00

Updated: 2004-12-28 06:54:00

Kuhnil Pharmaceutical recently acquired the exclusive domestic marketing rights for Bronuck (bromfenac sodium hydrate), an ophthalmic solution manufactured by Japan’s Senju Pharmaceuticals Co. Ltd.

Bronuck is a topical, twice daily, non-steroidal anti-inflammatory solution for the treatment of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK